CAR-T CELL THERAPY FOR SOLID TUMOURS

NEWS: Enhanced CAR-T therapy clears solid tumours by finding ‘faint’ targets

Introduction

• CAR-T cell therapyà type of immunotherapy where a patient’s own T-cells (immune cells) are modified to identify and destroy cancer cells.
• It has been highly successful in blood cancers like leukaemia and lymphoma, but less effective in solid tumours like kidney or ovarian cancer.

Key Scientific Discovery

• Researchers found that tumour cells thought to lack proteins like CD70 actually contain very small amounts.
• These amounts are too low for current CAR-T therapies to detect.
• A gene controlling CD70 is suppressed by an enzyme called EZH2= reduces protein production, making cancer cells appear invisible to immune therapy.
• HIT Receptor–> Scientists developed a new receptor called HLA-independent T-cell (HIT) receptor.
• It allows T-cells to detect very low levels of cancer proteins.
• Unlike traditional CAR-T, HIT uses the body’s natural immune signalling system.
• It can identify cancer cells even when protein levels are extremely low.

Experimental Results

• HIT-based CAR-T cells: Eliminated hidden tumour cells, Achieved complete tumour removal in some cases, Worked in kidney, ovarian, and pancreatic cancers

Comparison with Traditional CAR-T

• Traditional CAR-T: Shrinks tumours initially, Fails due to hidden cells
• HIT CAR-T: Detects faint targets, Prevents tumour regrowth

Key Takeaways

• CAR-T therapy works well in blood cancers but struggles in solid tumours.
• Main issue: tumour cells hiding due to low antigen levels.
• New HIT receptor allows detection of faint cancer signals.
• Promising results in animal studies, but safety and human trials remain challenges